BACKGROUND: Breast cancer incidence in sub-Saharan Africa (SSA) is increasing, and SSA has the highest age-standardized breast cancer mortality rate worldwide. However, high-quality breast cancer data are limited in SSA. MATERIALS AND METHODS: We examined breast cancer patient and tumor characteristics among women in Lilongwe, Malawi and evaluated risk factor associations with patient outcomes. We consecutively enrolled 100 women ≥ 18 years with newly diagnosed, pathologically confirmed breast cancer into a prospective longitudinal cohort with systematically assessed demographic data, HIV status, and clinical characteristics. Tumor subtypes were further determined by immunohistochemistry, overall survival (OS) was estimated using Kaplan-Meier methods, and hazards ratios (HR) were calculated by Cox proportional hazard analyses. RESULTS: Of the 100 participants, median age was 49 years, 19 were HIV-positive, and 75 presented with late stage (III/IV) disease. HER2-enriched and triple-negative/basal-like subtypes represented 17% and 25% tumors, respectively. One-year OS for the cohort was 74% (95% CI 62-83%). Multivariable analyses revealed mortality was associated with HIV (HR, 5.15; 95% CI 1.58-16.76; p = 0.006), stage IV disease (HR, 8.86; 95% CI 1.07-73.25; p = 0.043), and HER2-enriched (HR, 7.46; 95% CI 1.21-46.07; p = 0.031), and triple-negative subtypes (HR, 7.80; 95% CI 1.39-43.69; p = 0.020). CONCLUSION: Late stage presentation, HER2-enriched and triple-negative subtypes, and HIV coinfection were overrepresented in our cohort relative to resource-rich settings and were associated with mortality. These findings highlight robust opportunities for population- and patient-level interventions across the entire cascade of care to improve breast cancer outcomes in low-income countries in SSA.
BACKGROUND:Breast cancer incidence in sub-Saharan Africa (SSA) is increasing, and SSA has the highest age-standardized breast cancermortality rate worldwide. However, high-quality breast cancer data are limited in SSA. MATERIALS AND METHODS: We examined breast cancerpatient and tumor characteristics among women in Lilongwe, Malawi and evaluated risk factor associations with patient outcomes. We consecutively enrolled 100 women ≥ 18 years with newly diagnosed, pathologically confirmed breast cancer into a prospective longitudinal cohort with systematically assessed demographic data, HIV status, and clinical characteristics. Tumor subtypes were further determined by immunohistochemistry, overall survival (OS) was estimated using Kaplan-Meier methods, and hazards ratios (HR) were calculated by Cox proportional hazard analyses. RESULTS: Of the 100 participants, median age was 49 years, 19 were HIV-positive, and 75 presented with late stage (III/IV) disease. HER2-enriched and triple-negative/basal-like subtypes represented 17% and 25% tumors, respectively. One-year OS for the cohort was 74% (95% CI 62-83%). Multivariable analyses revealed mortality was associated with HIV (HR, 5.15; 95% CI 1.58-16.76; p = 0.006), stage IV disease (HR, 8.86; 95% CI 1.07-73.25; p = 0.043), and HER2-enriched (HR, 7.46; 95% CI 1.21-46.07; p = 0.031), and triple-negative subtypes (HR, 7.80; 95% CI 1.39-43.69; p = 0.020). CONCLUSION: Late stage presentation, HER2-enriched and triple-negative subtypes, and HIV coinfection were overrepresented in our cohort relative to resource-rich settings and were associated with mortality. These findings highlight robust opportunities for population- and patient-level interventions across the entire cascade of care to improve breast cancer outcomes in low-income countries in SSA.
Entities:
Keywords:
Breast cancer; Global health; Sub-Saharan Africa
Authors: Anna E Coghill; Eric A Engels; Maria J Schymura; Parag Mahale; Meredith S Shiels Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506
Authors: Jan A C Hontelez; Sake J de Vlas; Rob Baltussen; Marie-Louise Newell; Roel Bakker; Frank Tanser; Mark Lurie; Till Bärnighausen Journal: AIDS Date: 2012-07-31 Impact factor: 4.177
Authors: Racquel E Kohler; Satish Gopal; Anna R Miller; Clara N Lee; Bryce B Reeve; Bryan J Weiner; Stephanie B Wheeler Journal: Patient Educ Couns Date: 2016-08-09
Authors: Anna E Coghill; Polly A Newcomb; Margaret M Madeleine; Barbra A Richardson; Innocent Mutyaba; Fred Okuku; Warren Phipps; Henry Wabinga; Jackson Orem; Corey Casper Journal: AIDS Date: 2013-11-28 Impact factor: 4.177
Authors: Edmund M Der; Richard K Gyasi; Yao Tettey; Lawrence Edusei; Marcel T Bayor; Evelyn Jiagge; Mawuli Gyakobo; Sofia D Merajver; Lisa A Newman Journal: Breast J Date: 2015 Nov-Dec Impact factor: 2.431
Authors: Davies Adeloye; Olaperi Y Sowunmi; Wura Jacobs; Rotimi A David; Adeyemi A Adeosun; Ann O Amuta; Sanjay Misra; Muktar Gadanya; Asa Auta; Michael O Harhay; Kit Yee Chan Journal: J Glob Health Date: 2018-06 Impact factor: 4.413
Authors: Grace K Ellis; Agness Manda; Hillary Topazian; Christopher C Stanley; Ryan Seguin; Caroline E Minnick; Blessings Tewete; Asekanadziwa Mtangwanika; Mena Chawinga; Sara Chiyoyola; Maria Chikasema; Ande Salima; Stephen Kimani; Edwards Kasonkanji; Victor Mithi; Bongani Kaimila; Matthew S Painschab; Satish Gopal; Katherine D Westmoreland Journal: Int Health Date: 2021-04-27 Impact factor: 2.473
Authors: Alyssa E Tilly; Grace K Ellis; Jane S Chen; Agness Manda; Ande Salima; Asekanadziwa Mtangwanika; Blessings Tewete; Bongani Kaimila; Edwards Kasonkanji; Ella Kayira; Maria Chikasema; Ruth Nyirenda; Samuel Bingo; Sara Chiyoyola; Ryan Seguin; Satish Gopal; Takondwa Zuze; Tamiwe Tomoka; Katherine D Westmoreland Journal: JCO Glob Oncol Date: 2022-02
Authors: Yoanna S Pumpalova; Oluwatosin A Ayeni; Wenlong Carl Chen; Daniel S O'Neil; Sarah Nietz; Boitumelo Phakathi; Ines Buccimazza; Sharon Čačala; Laura W Stopforth; Hayley A Farrow; Maureen Joffe; Witness Mapanga; Judith S Jacobson; Katherine D Crew; Herbert Cubasch; Paul Ruff; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2021-06-14 Impact factor: 4.624